Alle Fälle anzeigen
ACT 16112/2024
—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Verfahrensdetails
- Status—VerfahrensartVerletzungKategorieHauptverletzungsklage
- Parteien
- Kläger
- Sanofi SA (successor of Sanofi Mature IP)
- Sanofi Winthrop Industrie
- Sanofi-Aventis GmbH
- Sanofi Belgium
- Sanofi-Aventis Deutschland GmbH
- Sanofi S.r.l.
- Sanofi B.V.
- Sanofi - Produtos Farmaceuticos Lda
- Sanofi AB
- Sanofi A/S
Vertreter: Frédéric Chevallier (McDermott Will & Schulte)Beklagte- Accord Healthcare B.V.
- Accord Healthcare, Unipessoal Lda.
- Accord Healthcare S.L.U.
- Accord Healthcare GmbH
- Accord Healthcare Italia Srl
- Accord Healthcare AB
- STADAPHARM GmbH
- STADA Arzneimittel AG
- STADA Nordic ApS
- Reddy Pharma SAS
- betapharm Arzneimittel GmbH
- Dr Reddy's Srl
- Zentiva France
- Zentiva Pharma GmbH
- Zentiva, k.s.
Vertreter: Jules Fabre (Taylor Wessing); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing) - Division
- Munich LD
- Richter
- Matthias Zigann · Presiding Judge and Judge-Rapporteur
- Technology
- Pharmaceuticals · Oncology · Pharmaceutical & Medical
- Sprache
- —
- Erste Entscheidung
- 15. Sept. 2025
Entscheidungen
- 2025-09-15Infringement Action
The Munich Local Division issued a post-interim-conference procedural order in consolidated infringement actions by Sanofi (and successor entities) against multiple generic companies (Accord, STADA, Dr Reddy's, Zentiva) relating to EP 2 493 466 (UPC_CFI_145–503/2024 group). The order confirmed oral hearing dates (14–17 October 2025) and directed that the four counterclaims for revocation be heard together while each infringement action is heard separately.
Rechtsfragen:Scheduling of consolidated oral hearingsJoint hearing of counterclaims with separate infringement actionsPharmaceutical patent — multiple generic defendants
Dokumente
- E79ADC9623FEEA58E3BCCD3E3CEC9B1C_en.pdf2025-09-15EN